Latest Breaking News On - Supplemental new drug application - Page 1 : vimarsana.com

Avadel Reports Uptick in Lumryz Therapy Adoption for Narcolepsy

Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

John Browning, MD: Potential Impact of FDA Acceptance of Tapinarof on Eczema Management

Discussing the Potential Approval of Tapinarof for Atopic Dermatitis with John Browning, MD

TAR-210 results show 90 percent recurrence-free survival

Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor...

Rx Rundown: Pfizer, Walmart, Novartis and more

SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

– Achieved $21.0 million in OGSIVEO® net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – ...

Dermatology Month in Review: April 2024

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

Tapinarof Cream for Adult, Pediatric Eczema Under FDA Review

A decision on approval is expected in the fourth quarter of 2024.

FDA Accepts Supplemental New Drug Application for Tapinarof Cream, 1%, in Atopic Dermatitis

The acceptance is based on positive data from the phase 3 ADORING 1 and ADORING 2 pivotal trials, as well as interim results from the phase 3 ADORING 3 open-label, long-term extension trial.